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Homeostatic synaptic scaling in response to neuronal stimulus or activation, and due to
changes in cellular niche, is an important phenomenon for memory consolidation, retrieval,
and other similar cognitive functions (Turrigiano and Nelson, 2004). Neurological disor-
ders and cognitive disabilities in autism, Rett syndrome, schizophrenia, dementia, etc.,
are strongly correlated to alterations in protein expression (both synaptic and cytoplasmic;
Cajigas et al., 2010). This correlation suggests that efficient temporal regulation of synap-
tic protein expression is important for synaptic plasticity. In addition, equilibrium between
mRNA processing, protein translation, and protein turnover is a critical sensor/trigger for
recording synaptic information, normal cognition, and behavior (Cajigas et al., 2010).Thus a
regulatory switch, which controls the lifespan, maturation, and processing of mRNA, might
influence cognition and adaptive behavior. Here, we propose a two part novel hypothe-
sis that methylation might act as this suggested coordinating switch to critically regulate
mRNA maturation at (1) the pre-transcription level, by regulating precursor-RNA process-
ing into mRNA, via other non-coding RNAs and their influence on splicing phenomenon,
and (2) the post-transcription level by modulating the regulatory functions of ribonucle-
oproteins and RNA binding proteins in mRNA translation, dendritic translocation as well
as protein synthesis and synaptic turnover. DNA methylation changes are well recognized
and highly correlated to gene expression levels as well as, learning and memory; however,
RNA methylation changes are recently characterized and yet their functional implications
are not established. This review article provides some insight on the intriguing conse-
quences of changes in methylation levels on mRNA life-cycle. We also suggest that, since
methylation is under the control of glutathione anti-oxidant levels (Lertratanangkoon et al.,
1997), the redox status of neurons might be the central regulatory switch for methylation-
based changes in mRNA processing, protein expression, and turnover. Lastly, we also
describe experimental methods and techniques which might help researchers to evaluate
the suggested hypothesis.
Keywords: alternative splicing, FMRP, glutathione, homeostatis, redox status, Rett syndrome,
S-adenosylmethionine, synaptic scaling
METHYLATION AFFECTS PRECURSOR-RNA PROCESSING
AND mRNA SYNTHESIS
METHYLATION BASED MODULATORY ROLE OF MICRORNAs
Precursor-RNA (Pre-RNA) is the immature and the incompletely
processed mRNA molecule in the nucleus and which needs to
be processed before exporting it into cytoplasm in fully functional
mature mRNA form. The pre-RNA processing is an early yet highly
regulated event in protein synthesis, wherein regulatory-RNAs
(re-RNA) and RNA binding proteins (RNABPs) exert dynamic
control. Micro-RNAs (mi-RNA) and other non-coding RNAs [nc-
RNA; e.g., long non-coding RNAs (lnc-RNAs)], are the major
re-RNAs involved in pre-RNA processing and are capable of induc-
ing alterations in gene expression. A functional complementation
exists between the levels of DNA methylation and mi-RNA func-
tion (Su et al., 2011) and expression (Saito et al., 2006; Chuang
and Jones, 2007). In addition, mi-RNAs, small nucleolar RNA
(sn-RNA), and anti-sense RNA can regulate the levels of DNA
methylation (Qureshi and Mehler, 2010). Hence, a highly sophis-
ticated dynamic regulatory network exists, which involves inter-
twined processes, (1) Methylation and (2) multifaceted actions
of various non-protein coding RNAs (Weber et al., 2007). This
proposal of an interactive loop corresponds to one discussed by
authors Bernstein and Allis (2005), wherein the authors indicate
the role of nc-RNAs like mi-RNAs, ribosomal-RNA, and transfer-
RNA in DNA methylation and transcription, as well as, how some
of these RNA molecules are themselves regulated by levels of DNA
methylation and methyl binding proteins like MeCP2. (Mehler
and Mattick, 2007).
Apart from a DNA methylation role, the mechanism through
which mi-RNA or other nc-RNAs regulate pre-RNA processing
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is not clearly identified. However, experts suggest involvement of
mi-RNA and anti-sense RNA to sequester the processing site for
mRNA transcripts and not allow normal mRNA binding. This
competition between pseudogenes and mRNA for regulation of
the processing site by mi-RNA has recently surfaced and is termed
as “the competitive endogenous RNA” (ce-RNA) theory of mRNA
translation and processing (Salmena et al., 2011). Interestingly, this
processing site for regulation of mRNA translation has also been
suggested to provide an intrinsic layer of control over expression
patterns of mRNA (Rigoutsos and Furnari, 2010). In addition,
apart from it’s role in the nucleus mi-RNA also plays a regula-
tory role at the synapse. This is exemplified via their influence on
the function of proteins like Fragile X mental retardation protein
(FMRP; Mehler and Mattick, 2007), which is involved in mRNA
translation and synaptic transport of about 400 different tran-
scripts (Santoro et al., 2011) including several synaptic proteins
and proteins involved in neural development as suggested by San-
toro et al. (2011) Reports suggest a correlation between the decline
in synaptic localization of proteins and observed neurological dis-
orders, for example: SHANK3 in autism spectrum disorders (ASD;
Durand et al., 2007) Neuroligin, neurexin, and PSD-95 (Warren,
2011) in Rett syndrome (Sudhof, 2008) and Fragile X syndrome
(Wang et al., 2007). Interestingly, some of these neurological dis-
orders are also associated with the malfunction of FMRP. (Darnell
et al., 2011; Santoro et al., 2011).
RNABP METHYLATION AND REGULATION OF ALTERNATIVE SPLICING
PATTERNS
Alternative splicing is one of the earliest phenomena to be iden-
tified as a “coding language” used by RNA molecules to gener-
ate protein diversity. Alternative splicing occurs by selective and
guided skipping of intragenic sequences during transcription and
pre-RNA processing. However, over the past decade it has been
shown that patterns of alternative splicing are not just involved
in protein diversity for evolutionary and developmental purposes,
but they also play a major regulatory role in pre-RNA process-
ing. This newly identified role of alternative splicing is especially
important in neurons, as it affects cell fate determination, axon
guidance, and synaptogenesis (Li et al., 2007). Some experts con-
sider the process of alternative splicing in neurons as an ability
of mRNA to adapt and perform differential protein expression
in response to local stimulus, neuronal activation, or changes
in the neuronal niche, which ultimately promotes homeostasis
(Grabowski and Black, 2001; Lipscombe, 2005). Errors of splicing
phenomena in neurons have been shown to be involved in sev-
eral neuromuscular and neurological disorders, including spinal
muscular atrophy, fronto-temporal dementia, Fragile X syndrome
and Rett syndrome (Li et al., 2007). A similar regulatory role of
alternative splicing can be exemplified in FMRP expression and
function; for example, in Drosophila melanogaster the short iso-
form of FMRP (without the glutamine-asparagine domain) is
inadequate for participating in short and long term memory for-
mation (Banerjee et al., 2010). Deletion of the homologous region
(i.e., the C-terminal domain) in human FMRP does not allow
binding of kinesin, and thus consequently inhibits dendritic trans-
port of mRNA molecules (Dictenberg et al., 2008), and affects
synaptic plasticity.
The methylation status of the RNA-binding domain of RNABP
is believed to regulate splicing pattern on mRNA transcript (Young
et al., 2005). Methylcytosine binding protein-2 (MeCP2) recog-
nizes 5-methylcytosine on DNA and is a critical transcription fac-
tor implicated in neuro-developmental disorders, including Rett
syndrome and autism spectrum disorder (Chahrour et al., 2008).
Y-box-binding protein 1 (YBP1) is a RNA binding protein, which
interacts with MeCP2, and this conjugation critically regulates
splicing, such that mutations in YBP1 or MeCP2, or alterations
in MeCP2 levels (as observed in Rett syndrome), can affect mRNA
splicing patterns, and cause aberrant gene expression (Young et al.,
2005). Thus RNABP methylation status is an important regulator
of alternative splicing phenomena.
EFFECTS OF METHYLATION ON POST-TRANSCRIPTIONAL
REGULATION OF mRNA
METHYLATION OF RNA
Similar to various other post-transcriptional modifications, RNA
methylation also occurs on different RNA species like tRNA,
rRNA,mRNA,tmRNA,sn-RNA,snoRNA,mi-RNA,and viral RNA
(Motorin and Helm, 2011). In fact, RNA methylation occurs at
different positions and a variety of RNA-methyltransferases are
employed for this process. It is a post-transcriptional modifica-
tion, dependent on the levels of S-adenosylmethionine (SAM),
which serves as the methyl donor (Figure 1A; Martin, 1992). The
most common and highly studied RNA methylation is involved in
the process of “capping” at the 5′ end. The guanosine nucleotides
are methylated and this marking of eukaryotic mRNA allows cells
to distinguish host mRNA from other types of RNA molecules
including viral mRNA molecules.
Methylation of cytosine (5MeC), well-known for DNA, has also
been recently reported for RNA (Rozenski et al., 1999). However,
levels of 5MeC in RNA are low, and the major form of methylation
in RNA (i.e., about 30–50% of total RNA methylation) is reported
to occur at the 6-position on adenine residues (m6A; Martin, 1992).
5MeC has been described in RNA species like rRNA and tRNA
(Rozenski et al., 1999), whereas the highly conserved heteroge-
neous RNAs (hnRNA) show m6A residues (Yu, 2011). However, the
methylated 6-adenine (m6A) residue is localized in a general con-
sensus sequence, Gm6AC or Am6AC in almost all RNA transcripts
(Wei and Moss, 1977). Some studies discussed in this section also
indicate a significant correlation between alterations in m6A levels
and subsequent changes in mRNA processing activity. In particu-
lar, two separate studies demonstrated about a 1.5 fold elevation in
translation of dihydrofolate reductase (DHFR) RNA transcript in
correlation with an increase in its level of methylation on mRNA
transcripts (Heilman et al., 1996), whereas inhibition of methyla-
tion capacity by depleting SAM levels led to a decrease in DHFR
transcript processing (Tuck et al., 1999). Levels of m6A also regulate
the selection of splicing sites, and supporting evidence shows that
SAM depletion disrupts splicing patterns, and decreases cytoplas-
mic and consequently synaptic localization of mRNA molecules
(Caboche and Bachellerie, 1977).
BC1, a small non-coding RNA (snc-RNA) is highly expressed
in neurons (Muslimov et al., 2002) and enriched at synapses (Chi-
curel et al., 1993). It forms a ribonucleoprotein (RNP) with several
partners including FMRP and acts as a liaison between FMRP
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FIGURE 1 | Summary of the hypothesis. (A)The relationship between the
methionine cycle of methylation and the transulfuration pathway which
converts HCY to cysteine. In brain, glial cells are a primary source of released
GSH, which is hydrolyzed to cysteine in the extracellular space. (Raps et al.,
1989; Hirrlinger et al., 2002) The intracellular availability of cysteine is
rate-limiting for GSH synthesis, and the GSH/GSSG-based redox status is
regulated through a combination of cysteine uptake and transsulfuration of
HCY. Redox status regulates the SAM/SAH level via its influence on
methionine synthase. More than 200 methylation reactions are dependent on
SAM levels; Key steps in mRNA processing are regulated via SAM-dependent
methylation. Levels of intracellular methionine affect protein synthesis, since
it is the required amino acid for initiation of translation. (B) An example of a
methyltransferase being regulated by redox status which affects neuronal
plasticity. PRMT is a SAM-dependent methyltransferase which methylates
the RGG domain of FMRP (a RNABP). FMRP is involved in regulation of about
400 different mRNA transcripts, including NLGN3 (neuroligin-3), PSD-95 (post
synaptic density protein-95) and the AMPA-type glutamate receptor. Thus
redox status, acting via methylation reactions, can control synaptic strength
between neurons, thereby providing a potential molecular mechanism for
Hebbian learning and memory formation.
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and FMRP’s target mRNA molecules (Zalfa et al., 2003). The
tudor domain of FMRP selectively binds to non-methylated BC1
(Zalfa et al., 2003, 2005). Recently, it has also been shown that
BC1 in intracellular compartments contains 2′-O-methylation in
the FMRP binding domain, whereas if present at synapses, BC1
lacks the 2′-O-methylation mark, which allows its FMRP inter-
action (Lacoux et al., 2012). Thus, the methylation status of BC1
indirectly regulates translation and mRNA processing at synapses
by regulating FMRP (Lacoux et al., 2012). Studies show that
hypomethylation of precursors and intermediates of ribosomal-
RNA in the nucleus inhibits their cytoplasmic export and prolongs
nuclear accumulation, thus inhibiting further RNA processing
(Dictenberg et al., 2008). In fact, Vaughan et al. (1967) showed
that depriving cells of methionine and limiting the methylation
capacity leads to a blockade of ribosome production itself. A sim-
ilar study with cycloleucine (a reversible inhibitor of nucleic acid
methylation) showed that hypomethylation affects the RNA matu-
ration process at different stages and results in altered mRNA levels
in a cumulative manner (Caboche and Bachellerie, 1977). All of
the above effects can result in alterations in mRNA translation,
and in neurons it might lead to protein deprivation at synapses
and hence hinder changes in synaptic plasticity. However, these
are preliminary results and further proof would be required to
support this idea.
RNA BINDING PROTEIN METHYLATION
mRNA biogenesis depends upon nuclear formation of a messen-
ger ribonucleoprotein particle (mRNP), which is then exported
to the cytoplasmic compartment (Yu, 2011). RNABPs regulate a
highly dynamic, yet well-orchestrated molecular organization and
recognition pattern for mRNP formation. Arginine methylation,
which is a major feature of post-transcriptional regulation, occurs
on almost all RNABPs, including heterogeneous RNP (hnRNP)
and serine/arginine-rich (SR) proteins (Bedford and Clarke,2009).
Arginine methylation is implicated in various cellular processes
including, but not limited, to transcription and RNA processing,
which includes nuclear export and synaptic localization of mRNA
(Yu,2011). In mammals, the process of arginine methylation is per-
formed by about 10 known protein arginine methyltransferases
(PRMTs), whose activity is dependent on levels of SAM as the
methyl group donor (Bedford and Clarke, 2009). Thus depletion
of SAM decreases PRMT methylation of FMRP (Santoro et al.,
2011), which alters processing of mRNA transcript associated with
FMRP.
As mentioned above, RNABP methylation occurs at a specific
consensus domain known as “RGG” (arginine flanked by glycine)
(Bedford and Clarke, 2009). The RGG domain in RNABP rec-
ognizes a particular mRNA transcript and selectively binds to
it, which results in mRNA translation and/or transport. Indeed,
studies involving FMRP show that alterations in the level of RGG
methylation are closely associated with changes in protein-protein
and protein-RNA interactions (Dolzhanskaya et al., 2006). In the
case of FMRP, it was also suggested that differential RGG methy-
lation levels in FMRP can strongly affect the affinity of FMRP
for about 400 different mRNA transcripts, about 95 of which
belong to proteins involved in synapse formation, and approx-
imately 28 of these proteins are implicated in autism (Santoro
et al., 2011). Preliminary results implicate a similar regulatory
role of methylation status of mRNA transcript in the KH2 type
RNA-binding domain of RNABP, in RNA-RNABP kissing com-
plex formation (De Boulle et al., 1993). A I304N mutation in the
KH2 domain of FMRP blocks its ability to bind to polyribosomes
and regulate RNA processing (Feng et al., 1997). Additionally,
investigators have generated mouse models for Fragile X syn-
drome carrying this I304N mutation in the KH2 domain of FMRP,
and have showed specifically that lost RNA binding ability (due
to mutation) led to decrease in FMRP levels and polyribosome
association (Zang et al., 2009). In addition, a similar mutation
is observed in the KH2 RNA-binding domain in post-mortem
brain samples from Fragile X syndrome patients (De Boulle et al.,
1993). Similarly, several other proteins possessing a conserved
RGG domain play an important role in pre-RNA processing (e.g.,
“RGG” methylation in spliceosomal small nuclear ribonucleopro-
teins (snRNPs) regulates alternative splicing). Hence, binding of
RNA to RNABP and formation of mRNPs during transcription is
a dynamic yet ordered process, and a number of factors involved
in the process, appear to be influenced by methylation capacity
and levels of methylation on RNA as well as RNABP.
REGULATION OF PROTEIN TURNOVER VIA METHYLATION
CAPACITY
Protein arginine methylation, the process of adding monomethyl
or dimethyl groups to arginine residues, is a well-known methy-
lation reaction (Gary and Clarke, 1998). About 12 ATPs are
required per methylation cycle and evolutionary retention of such
an “expensive” system underscores the biological importance of
this post-translational modification (Boisvert et al., 2003). His-
tone arginine methylation and myelin basic protein were the first
proteins known to be methylated (Paik and Kim, 1968; Brostoff
and Eylar, 1971). At present, more than 200 proteins are known to
contain RG-repeats and can be methylated at arginine residue by
different classes of PRMT (Boisvert et al., 2003). Most of these pro-
teins are associated with RNA maturation process as mentioned
earlier, and are involved in mRNA translation regulation through
RNABP (Boisvert et al., 2003). Thus, all these studies support
the general concept that protein arginine methylation regulates
localization and turnover of synaptic proteins.
Methionine is the initiating amino acid for protein synthesis,
as the starting codon sequence “AUG” on any mRNA molecule
corresponds to methionine. Hence, intracellular levels of methio-
nine can regulate initiation of protein synthesis. Lower methionine
availability (for methionine-loaded MET-tRNA) would result in
decreased initiation of translation, affecting a wide range of cellu-
lar functions. In neurons this could decrease the rate of synaptic
protein synthesis, limiting the ability to dynamically adjust the
composition of the proteome in accordance to changes in neuronal
niche. Importantly, protein lifespan depends partly upon the ubiq-
uitinylation of exposed lysine residues at their epsilon amino group
in a protein which targets these proteins for proteasomal degrada-
tion. However, methylation or homocysteinylation of these sites
will block ubiquitination and extend protein lifespan, allowing
integration with protein synthesis (Shukla et al., 2009; Williamson
and Whetton, 2011). Thus, the equilibrium between levels of
methionine (MET) and homocysteine (HCY) is important for
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normal translation, and protein turnover. This would act as a reg-
ulatory point for modulating protein homeostasis at synapses, thus
regulating synaptic plasticity.
CENTRAL REGULATORY REDOX SWITCH
The methylation potential depends on levels of SAM and SAH,
as described above and as indicated in Figure 1A. However, lev-
els of SAM are in turn dependent upon the levels of methionine,
homocysteine, and activity of the folate and vitamin B12 depen-
dent enzyme methionine synthase (Figure 1A). Most importantly,
methionine synthase activity is highly sensitive to cellular redox
status and to fluctuations in the major intracellular anti-oxidant,
glutathione (GSH; Waly et al., 2004). The methyl group donated
by SAM derives from adenosylation of methionine, and dur-
ing all SAM-dependent methylation reactions, donation of this
methyl group results in S-adenosylhomocysteine (SAH), which is
an inhibitor of methylation, based upon its competition with SAM
for methyltransferase binding (Yi et al., 2000). SAH is reversibly
converted to HCY by SAH hydrolase, whose activity affects the
rate of methylation reactions (Chiang et al., 1996). Methionine
synthase, which forms MET from HCY, also regulates SAM levels,
as indicated in Figure 1A. More than 200 methylation reactions
(including DNA and RNA methylation) are dependent upon the
SAM/SAH ratio (Petrossian and Clarke, 2011). Interestingly, one
of the most widely accepted causes of DNA and RNA damage in a
cell is oxidative stress, which is induced by a decline in levels of the
major anti-oxidant GSH. Levels of GSH in neurons can be main-
tained by HCY and MET through the intermediates cystathionine
and cysteine. Abnormal levels of these metabolites, including cys-
teine, GSH, SAM, and SAH have been extensively demonstrated in
ASD (James et al., 2004; Deth et al., 2008). In addition, redox levels
have also been directly linked to regulation of mRNA (Ufer et al.,
2010) as well as micro-RNA (Wiesen and Tomasi, 2009; Ufer et al.,
2010). However, the reader is asked to seek further literature from
the references cited above. Thus, anti-oxidant levels can regulate
SAM/SAH-based methylation reactions throughout the cell, with
implications for the clinical pathophysiology of neurological and
neuro-developmental disorders.
The concept of a redox-based methylation switch for mRNA-
related events requires validation through experimental inves-
tigation of the hypothesis we put forth. Recent technological
advancements allow individual mRNA transcript sequencing as
well as whole transcriptome sequencing using the SOLiD™sys-
tem (Lao et al., 2009). Hence, methylation changes on mRNA
transcripts in animal models of neurological disorders (e.g., Rett
syndrome, ASD, etc.), as well as in post-mortem brain samples
of patients suffering from these disorders, can be measured at
the individual mRNA transcript level. Bisulfite sequencing can
be used to measure methylation status in the whole transcrip-
tome, and population-based transcriptome comparisons can be
analyzed (Schaefer et al., 2009). In addition, a cause-effect rela-
tionship between levels of methylation in mRNA/RNABP or other
such effectors, and resulting neurological or behavioral effects,
should also be investigated. This is exemplified by the correl-
ative studies described above, involving the FMRP methylat-
ing enzyme PRMT and resulting neurological changes observed
with its decreased activity (Figure 1B; Santoro et al., 2011). In
addition, manipulations of the redox state in neuronal cells can be
altered by oxidative insults and/or anti-oxidant interventions (e.g.,
N -acetylcysteine or GSH). Comparisons of subsequent changes
in mRNA methylation patterns across the transcriptome or in
individual transcripts can be measured by bisulfite sequencing,
as described above, as well as by mass spectrometry (Qiu and
McCloskey, 1999).
Some of the experiments suggested above are exemplified
from studies performed by researchers in Germany (Hermes
et al., 2004). In this study, researchers manipulated redox con-
ditions and investigated subsequent effects on methylation poten-
tial (SAM/SAH levels) and alterations in levels of mRNA and
DNA methylation. They induced hypoxia in HepG2 cell cul-
tures, which led to increased SAM and decreased SAH levels with
about four-fold elevation in methylation potential (Hermes et al.,
2004). Real-time PCR amplification quantified specific mRNA
transcripts, namely VEGF and erythropoietin. Incorporation of
radiolabeled l-[methyl-3[H]-methionine] and 14[C]-uridine into
mRNA reported that inhibition of SAH hydrolase led to decreased
methylation potential and decreased mRNA methylation, which
suggested that increased SAH levels led to probable inhibition of
mRNA-methyltransferase, which is consistent with reports from
other studies (Backlund et al., 1986). Similar studies could be
performed for neuronal cell cultures and with advanced tech-
niques like FRAP (fluorescence recovery after photobleaching),
the synaptic localization or transport of proteins could be tested
(Antar et al., 2005). Additionally, by keeping animals/cell cul-
tures in a hypobaric or hyperbaric oxygen chamber and using
optogenetic tools to selectively stimulate a certain population of
cells involved in particular brain function, correlations could be
made between brain activity, redox status, and synapse forma-
tion. For these purposes, redox status could be evaluated by using
magnetic resonance imaging (MRI) or single-photon emission
computed tomography (SPECT) to image 99mTechnetium hexam-
ethylpropyleneamine oxime (HMPAO) conjugated to glutathione
(Suess et al., 1991). Post-mortem gene expression analysis could
then be performed in addition to quantification of mRNA and
DNA methylation status using techniques described above. These
and other such studies would allow researchers to test the under-
lying major hypothesis that redox state is the ultimate source of
regulatory control over mRNA methylation, mRNA processing,
protein synthesis, and protein turnover.
CONCLUSION
Thus, evidence from a number of studies indicates that, methy-
lation capacity and methylation levels of mRNA play a major
role in it’s maturation and processing, which further affects pro-
tein expression and synaptic localization. Any alterations in these
key phenomena can trigger an array of effects which might
terminally result in neurological disorders. Redox status adds
another intricate layer to the sparsely clarified processes mentioned
above. However, redox state should be considered as a powerful
tool, which can be manipulated to study mRNA regulation and
strengthen our current insights of basic biological processes.
The temporospatial localization of proteins is important for
synaptic plasticity and a redox-based methylation switch provides
modulation of mRNA maturation and lifespan, which eventually
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influences protein homeostasis at synapses and influences higher-
order cognitive functions. A “holonarchy” for synaptic plasticity
can be imagined, beginning at mRNA synthesis, transcription,
translation, protein turnover, methylation reactions, and at the
highest level redox status serves as the central regulatory switch.
All these biological processes are individually highly dynamic and
complex, yet they are well-coordinated and interrelated processes
which provide feedback regulation to each other in order to control
and maintain homeostatic synaptic plasticity. However, significant
additional evidence supporting this hypothesis is needed, which
will not only help in clarifying the functional linkage between key
regulatory factors like mi-RNA, RNABPs, GSH, and SAM/SAH,
but will also identify potential targets for treating neurological
disorders like ASD, Fragile-X syndrome, and other synaptic pro-
tein deficiency disorders which can result from defects in mRNA
maturation and processing.
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